MyFinsight
Home
Blog
About
something is missing
$108,154K
Proceeds from offering of
common stock, net of...
$54,861K
(-49.28%↓ Y/Y)
Proceeds from exercises
of stock options
$1,721K
(135.43%↑ Y/Y)
Proceeds from employee
stock purchase plan
$66K
(11.86%↑ Y/Y)
Net cash provided by
financing activities
$164,357K
(38.00%↑ Y/Y)
Canceled cashflow
$445K
Net increase in cash
and cash...
$34,890K
(-57.94%↓ Y/Y)
Canceled cashflow
$129,467K
Payments of offering
costs
$445K
(-24.58%↓ Y/Y)
Proceeds from maturities
of...
$41,650K
(29.77%↑ Y/Y)
Stock-based compensation
$3,272K
(26.23%↑ Y/Y)
Accrued expenses and
other liabilities
$685K
(168.30%↑ Y/Y)
Operating lease
right-of-use assets
$102K
(-54.05%↓ Y/Y)
Depreciation and
amortization
$34K
(-54.67%↓ Y/Y)
Net cash used in
investing activities
-$112,038K
(-791.95%↓ Y/Y)
Net cash used in
operating activities
-$17,429K
(26.08%↑ Y/Y)
Canceled cashflow
$41,650K
Canceled cashflow
$4,093K
something is missing
$13,192K
Interest income, net
$4,392K
(73.46%↑ Y/Y)
Purchases of
available-for-sale marketable...
$153,564K
(243.88%↑ Y/Y)
Net loss
-$17,797K
(21.39%↑ Y/Y)
Purchases of property,
equipment and leasehold...
$124K
Canceled cashflow
$17,584K
Prepaid expenses and
other current assets
$2,932K
(82.57%↑ Y/Y)
Accretion of
available-for-sale marketable...
$517K
(-33.55%↓ Y/Y)
Accounts payable
-$276K
(37.13%↑ Y/Y)
Employee compensation
(excluding stock...
$6,506K
(12.66%↑ Y/Y)
Chronic cough in ipf
clinical trial expense
$6,034K
(1.91%↑ Y/Y)
Stock-based compensation
expense
$5,463K
(110.76%↑ Y/Y)
Other segment items
$4,554K
(1.81%↑ Y/Y)
Clinical trial material
$3,904K
(592.20%↑ Y/Y)
Other clinical
development expenses
$3,371K
(2.81%↑ Y/Y)
Refractory chronic cough
clinical trial expense
$3,106K
(148.08%↑ Y/Y)
Other clinical trials
and studies
$2,443K
(85.50%↑ Y/Y)
Back
Back
Cash Flow
Trevi Therapeutics, Inc. (TRVI)
Trevi Therapeutics, Inc. (TRVI)
source: myfinsight.com